You are reading this week’s edition of New Cannabis Ventures, a weekly magazine we have published since October 2015. The newsletter includes unique insight to help our readers stay ahead of the curve, as well as links to the most important news of the week. We no longer email them like we used to, but post this and all newsletters on our website here.

friends,

A year ago, people were extremely excited about the American hemp industry. President Biden had made his 2022 proposal and was pushing realignment, and it was underway. Also, Florida was on the verge of legalization for adults. The Global Hemp Stock Index closed at 8.22 on 10/31 and is now down 14.7% to close at 7.01 on 10/29, up just 1.9% year-to-date. Big ETF MSOS, which recently closed at 4.52, a premium to net asset value of 4.48, is up 18.6% year-to-date but down 31.5% since the end of October a year ago. Looking at the 5 largest MSOs since then, they have all declined;

In 2025, they all increased except for Green Thumb Industries, which decreased by 14.1%. GTI has the best balance sheet of these five companies. The worst balance belongs to Curaleaf, which is down just 1% since last Halloween and is up a staggering 83.3% in 2025.

In my opinion, things can get very scary. It is not clear to me who is doing this, but someone is playing a big game with MSOS. The ETF has seen its share count grow 44.2% so far in 2025, which is a huge increase. MSOs have very low valuations and have fallen badly in the last almost five years after peaking in early 2021, but if the 280E taxation remains, they could be crushed by their balance sheets and cash flows.

Games are moving out of the MSO space, with many traders rolling the dice on Tilray Brands. Over the past month, the stock has averaged more than 108 million shares in a day’s trading. The stock is up 2.3% in 2025, in contrast to the Global Hemp Stock Index, but it has been volatile. Shares fell 41.4% after hitting a 52-week high after the company reported its fiscal quarter results on 10/9. Even with this big drop, it’s 288% above its all-time low in June. Sales and profits aren’t growing much, but the number of shares is certainly up. Oh, but it’s a collection of memes…

Last week’s newsletter included a table of annual returns for the 28 stocks in the Global Hemp Stock Index. Nine rose more than 20% and six fell more than 20%. A week later, there are still nine that have gained more than 20% (the same nine) and six that are down more than 20% (five previous members and one new member). Looking at the nine big winners, several had a tough week, falling after a more than 0.3% drop in the Global Hemp Stock Index;

Seven of these nine big winners in 2025 were down in October, and five were down more than the Global Hemp Stock Index this month. Trick, friends! Watch out for goblins.

Sincerely,

Alan:

New Cannabis Ventures publishes curated articles as well as exclusive news. Here is what we published last week.

Exclusives

Canadian hemp sales hit record highs in August

Financial:

Verano Q3 revenue down 6%

Follow Alan for real-time updates X.com:. You can also share and discover industry news with like-minded people on the largest group of cannabis investors and entrepreneurs. LinkedIn:.

View: Public Hemp Company Revenue and Earnings Trackingwhich ranks the highest-earning hemp stocks.

Stay on top of the most important communications from public companies by watching what’s coming cannabis investor calendar.

Based in Houston, Alan leverages his experience as an online community founder 420 Investorthe first and still the largest due diligence platform focused on publicly traded stocks in the cannabis industry. With his extensive network in the cannabis community, Alan continues to find new ways to connect the industry and facilitate its sustainable growth. time New Cannabis Ventureshe is responsible for content development and strategic alliances. Before turning his attention to the cannabis industry in early 2013, Alan, who began his career on Wall Street in 1986, worked as an independent research analyst with more than two decades of research and portfolio management experience. A prolific writer, with over 650 articles published since 2007 Looking for Alphawhere he has 70,000 followers, Alan is a frequent speaker at industry conferences and frequent source Media including the NY Times, Wall Street Journal, Fox Business and Bloomberg TV. Contact Alan. Twitter: |: Facebook |: LinkedIn: |: El

You are reading this week’s edition of New Cannabis Ventures, a weekly magazine we have published since October 2015. The newsletter includes unique insight to help our readers stay ahead of the curve, as well as links to the most important news of the week. We no longer email them like we used to, but post this and all newsletters on our website here.

friends,

Hemp stocks have retreated significantly since the beginning of this month and are now down in October. The New Cannabis Ventures Global Cannabis Stock Index, which closed at 7.03, was down 8.5% in October. Annual growth is only 2.2%. After four consecutive declines in four years, the market is close to extending its losing streak.

MSOS closed at 4.44, a 1.5% discount to its NAV, and is down 7.3% in October, but up 16.5% year to date. Last week it was at 5.40, up 41.7% from the previous day and up 12.7% in October when I warned about upcoming financial statements. I looked at the monthly returns of the 9 MSOs in the American Hemp Operator Index and they ranged from +4.4% to +35.8% over that time. Now they are lower, with six of them recording losses.

Looking at the 7 largest MSOS positions, all are above 5%, with two, Curaleaf and Trulieve, above 21%, the best performer being Verano at 7.7% in October. The three largest positions were all down: Curaleaf, down 3.9%, Trulieve, down 8.8%, and Green Thumb Industries, down 9.9%.

The three largest positions to date are very different, with one double-digit decrease and two significant increases;

Looking at the other four majors, which range in size from 5.6% to 7.7%, they are all double-digit gainers;

• Glass house brands: +31.0%
• TerrAscend: +23.6%
• Cresco Labs: +21.5%
• Verano Holdings: +19.7%

These 7 largest MSOS positions are all in the Global Cannabis Stock Index, albeit with lower percentages for some and lower for all. While they mostly rallied in 2025, all have declined since last November’s election. As I discussed in last week’s newsletter, the current financial situation is not exciting at all. What drives them? A possible realignment which, if it happens, could eliminate 280E taxation.

There’s more to the cannabis sector than just MSOs, some of which have surged since late June. The index currently has members from five other subsectors, but only one from Biotech, only one from THC Beverage and only one from Canadian Retailers. MSOs make up 26.1% of the index, which is lower than Ancillaries at 39.1% and higher than Canadian LPs at 23.8%. I actually like the affiliate programs and still recommend them to investors look at hemp REITswhich I last discussed here on 8/14.

I was a big fan of Canadian LPs earlier this year, but my exposure in my 420 Investor model portfolio is only two names and slightly lower than index exposure. Canopy Growth, which I’ve disliked for a while, is one of the Canadian LPs in the index that I avoid. It is down 51.8% in 2025, but is up 28.2% since late July and 59.0% since April 8, its all-time closing low. I expect this one to make a new all-time low. The other Canadian LP I’m concerned about is Tilray Brands, which is up 9.0% year-to-date but is very expensive in my opinion. It has quadrupled from its all-time low four months ago. I think it could be pulled back dramatically.

Looking at all 28 members of the Global Hemp Stock Index, returns averaged 11.7% year-to-date, well ahead of the benchmark. The average return was 7.0%, also before the index return.

As I said above, the Global Hemp Stock Index is up just 2.2% year-to-date, which is worse than the return of cash. Stocks outside the sector have rallied, with the S&P 500 returning nearly 15% this year. Hemp stocks could come under pressure if stocks pull back again. I have also shared some other reasons like 280E taxation does not end. The hemp sector lacks institutional buy-in and strong growth. It has recently been promoted by traders, but it may not end 2025 well. Be careful.

Sincerely,

Alan:

New Cannabis Ventures publishes curated articles as well as exclusive news. Here is what we published last week.

Exclusives

Follow Alan for real-time updates X.com:. You can also share and discover industry news with like-minded people on the largest group of cannabis investors and entrepreneurs. LinkedIn:.

View: Public Hemp Company Revenue and Earnings Trackingwhich ranks the highest-earning hemp stocks.

Stay on top of the most important communications from public companies by watching what’s coming cannabis investor calendar.

Based in Houston, Alan leverages his experience as an online community founder 420 Investorthe first and still the largest due diligence platform focused on publicly traded stocks in the cannabis industry. With his extensive network in the cannabis community, Alan continues to find new ways to connect the industry and facilitate its sustainable growth. time New Cannabis Ventureshe is responsible for content development and strategic alliances. Before turning his attention to the cannabis industry in early 2013, Alan, who began his career on Wall Street in 1986, worked as an independent research analyst with more than two decades of research and portfolio management experience. A prolific writer, with over 650 articles published since 2007 Looking for Alphawhere he has 70,000 followers, Alan is a frequent speaker at industry conferences and frequent source Media including the NY Times, Wall Street Journal, Fox Business and Bloomberg TV. Contact Alan. Twitter: |: Facebook |: LinkedIn: |: El

It Public Hemp Company Revenue and Earnings Trackingrun by New Cannabis Ventures, ranks the leading cannabis companies. This update is our first since mid-August when we reviewed Q2 reports.

Tracking rules

This data-driven, fact-based search engine will be continually updated based on new financial filings so readers can stay up-to-date. Companies must file with the SEC or SEDAR and be current to be considered for inclusion. When we launched this resource in May 2019, companies with more than $2.5 million in quarterly revenue qualified. As the industry has grown and as more companies have gone public, we have raised the minimum several times, including $5 million in October 2019, $7.5 million in June 2020, up to $10 million in November 2020, $12.5 million in August 2021, $12.5 million in August 2021, and $202 in September 2021. million dollars. hemp industry, we raised the minimum again in May 2024. The senior roster has a minimum of US$50 million (C$70.2 million) and the junior roster now has a minimum of US$25 million (C$35.1 million).

Note on adjusted operating income

In May 2019, we added an additional measure, Adjusted Operating Income, which we detailed in our newsletter. The calculation takes reported operating income and adjusts it for any changes in the fair value of biological assets required under IFRS accounting. We believe this adjustment improves comparability between companies under IFRS and GAAP accounting. We note that operating income can often include one-time items such as stock compensation, inventory write-offs or public listing costs, and we encourage readers to understand how these non-cash items may impact quarterly financials. Many companies have moved from IFRS to US GAAP accounting, which has reduced our need to make adjustments. Please note that our rating only includes actual reported income and non pro forma income. We also note that companies with non-hemp operations must provide segment-level financial statements detailing not only revenue but also operating profit in order for their operating profit to be included in the tracking. Currently, Aurora Cannabis (NASDAQ: ACB ) (TSX: ACB ), Jazz Pharma (NASDAQ: JAZZ ) and Tilray (TSX: TLRY ) (NASDAQ: TLRY ) do not provide this information.

Tracker inclusion updates

At the time of our last update on August 13, 16 companies were eligible for inclusion on the senior lists, including 13 in USD and 3 in Canadian currency, and 11 companies on the junior list. Now, 14 companies denominated in US dollars and 5 denominated in Canadian dollars qualify for the senior lists, for a total of 19 now. The junior list includes 11 companies that report in US dollars and 1 in Canadian dollars. Tracking public cannabis company revenue and earnings on a combined basis now includes 31 companies. One company, Glass House Brands (OTC: GLASF) (NEO: GLAS.AU) moved from the American Junior list to the Senior list. Fluent (OTC: CNTMF) (CSE: FNT.U) has been added to the American Junior list. In Canada, Auxly Cannabis (OTC: CWBTF) (TSX: XLY) has joined the Junior List.

Companies that have reported since mid-August are included

There have been few reports since our last update, as most of these companies are operating at the end of December and meet earlier deadlines than the middle of the month.

Senior and Junior – US Dollar Report

Neither company has yet reported Q3, but updates will begin to trickle in next week. Tilray brands (NASDAQ: TLRY ) (TSX: TLRY ) reported its fiscal quarter earlier this month. The diversified company grew its cannabis business 5% year-over-year as it declined 5% sequentially. Overall for the company was up from a year ago, but adjusted EBITDA was lower than expected due to lower gross margin.

One major company that has diversified beyond cannabis, and Scotts Miracle-Gro (NYSE: SMG ), will report its fiscal 4th quarter by the end of the year. It has not yet scheduled the next conference call, although its website suggests 11/5 could be a tentative date.

Some of the 5 largest MSOs have scheduled calls for their Q3 financial reports, although GTI has changed its policy and will not be hosting any for now. Here is the current outlook of all of them.

• Curaleaf (OTC: CURLF ) (TSX: CURA ) – revenue is expected to decline 4% year-over-year to $317.1 million, with adjusted EBITDA of $66.4 million, a 12% decline.
• Trulieve (OTC: TCNNF ) (CSE: TRUL ) – Revenue is expected to increase 1% year-over-year to $296 million, and adjusted EBITDA is expected to decline less than 1% to $95.9 million, a 13% decline sequentially.
• Green Thumb Industries (OTC: GTBIF ) (CSE: GTII ) – revenue is expected to increase 1% year-over-year to $290.9 million and adjusted EBITDA is expected to decline 9% to $81.9 million.
• Verano Holdings (OTC: VRNOF ) (NEO: VRNO ) – revenue is expected to decline 6% to $208 million and adjusted EBITDA is expected to decline 6% to $60.7 million.
• Cresco Labs (OTC: CRLBF ) (CSE: CL ) – Revenue is expected to decline 9% to $163.7 million and adjusted EBITDA is expected to decline 29% to $36.5 million.

Senior and Junior – Canadian Dollar Report

Since our last update, only High Tide (NASDAQ: HITI ) (TSXV: HITI ) has reported among Canadian listed companies. Revenue was up sequentially in its fiscal quarter, and operating profit was just under $4 million.

One of Canada’s senior list members, SNDL, has scheduled its quarterly call.

The Public Cannabis Company Earnings Tracker by New Cannabis Ventures is not a recommendation of any company, and you should not use it as investment advice. A tilde next to a date means an approximate date. All calculations are derived from SEC or SEDAR filings. Any questions or licensing inquiries please contact us.

Did you miss something? Catch them all! Cannabis Revenue Tracking Updates.

Based in Houston, Alan leverages his experience as an online community founder 420 Investorthe first and still the largest due diligence platform focused on publicly traded stocks in the cannabis industry. With his extensive network in the cannabis community, Alan continues to find new ways to connect the industry and facilitate its sustainable growth. time New Cannabis Ventureshe is responsible for content development and strategic alliances. Before turning his attention to the cannabis industry in early 2013, Alan, who began his career on Wall Street in 1986, worked as an independent research analyst with more than two decades of research and portfolio management experience. A prolific writer, with over 650 articles published since 2007 Looking for Alphawhere he has 70,000 followers, Alan is a frequent speaker at industry conferences and frequent source Media including the NY Times, Wall Street Journal, Fox Business and Bloomberg TV. Contact Alan. Twitter: |: Facebook |: LinkedIn: |: El